Market Research Logo

Global Markets for Neglected Tropical Disease Treatments

Global Markets for Neglected Tropical Disease Treatments

The global market for neglected tropical diseases should reach $2.6 billion by 2021 from $1.4 billion in 2016 at a compound annual growth rate (CAGR) of 14.1%, from 2016 to 2021.

Report Includes
An overview of the global markets for tropical disease treatments.
Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
A look at the total addressable market, an indication of the number of people affected, and the current shares of key marketed therapies.
Representations of market shares by geography, company, and future outlook.
Insight on some of the newer drug candidates, clinical trials, and their end points.
Analyses of factors such as increases in resistance of vectors to common insecticides, increases in rapid diagnostic techniques, and no established treatment for newer conditions like Zika.
Profiles of major players in the industry.

Report Scope
The report focuses on newer drugs and innovations in chemical compounds, vaccines and biologicals recently launched or in development. Specifically excluded from the scope of research are vector or mosquito control approaches, strategies and products; drugs used for symptomatic treatment and not for the elimination of the virus from the host; and details on manufacturers and suppliers of nonbranded generics.

Products used for diagnosis as well as PCR techniques, kits and testing facilities are also excluded from the report.

BCC Research has categorized the markets based on regions defined by the WHO since it is the primary organization mapping disease prevalence, assisting with access to medicine and enabling partnerships. Regions include Africa, Americas, South-East Asia, Europe, Eastern Mediterranean and Western Pacific. These cover all the WHO participating countries which are described in detail in the subsequent section.


Chapter 1: Introduction
Study Goals and Objectives
Reasons for Doing this Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst’s Credentials
Related BCC Research Reports
Chapter 2: Summary and Highlights
Chapter 3: Disease Overview
Malaria
Incidence and Geographical Distribution
Etiology and Symptoms
Socioeconomic Burden
Current Method of Treatment
Leishmaniasis
Incidence and Geographical Distribution
Etiology and Symptoms
Socioeconomic Burden
Current Method of Treatment
Schistosomiasis
Incidence and Geographical Distribution
Etiology and Symptoms
Socioeconomic Burden
Current Method of Treatment
Lymphatic Filariasis
Incidence and Geographical Distribution
Etiology and Symptoms
Socioeconomic Burden
Current Method of Treatment
Chagas Disease
Incidence and Geographical Distribution
Etiology and Symptoms
Socioeconomic Burden
Current Method of Treatment
African Trypanosomiasis
Incidence and Geographical Distribution
Etiology and Symptoms
Socioeconomic Burden
Current Method of Treatment
Dengue
Incidence and Geographical Distribution
Etiology and Symptoms
Socioeconomic Burden
Current Method of Treatment
Ebola
Incidence and Geographical Distribution
Etiology and Symptoms
Socioeconomic Burden
Current Method of Treatment
Zika
Incidence and Geographical Distribution
Etiology and Symptoms
Socioeconomic Burden
Current Method of Treatment
Chapter 4: Market Overview
Total Addressable Market
Malaria
Malaria – Market Share by Geography
Leishmaniasis
Leishmaniasis – Market Share by Geography
Schistosomiasis
Schistosomiasis – Market Share by Geography
Lymphatic Filariasis
Lymphatic Filariasis – Market Share by Geography
Chagas Disease
Chagas Disease – Market Share by Geography
African Trypanosomiasis
Dengue
Dengue – Market Share by Geography
Ebola
Zika
Zika – Market Share by Geography
Donations by Pharmaceutical Companies: Access to Medicines
Chapter 5: Market Influencing Factors
Market Drivers
Malaria
Leishmaniasis
Lymphatic Filariasis
Chagas Disease
African Trypanosomiasis
Dengue
Ebola
Zika
Market Deterrents
Malaria
Leishmaniasis
Schistosomiasis
Lymphatic Filariasis
Chagas Disease
African Trypanosomiasis
Dengue
Ebola
Zika
Unmet Needs
Malaria
Leishmaniasis
Schistosomiasis
Lymphatic Filariasis
Chagas Disease
African Trypanosomiasis
Dengue
Ebola
Zika
Chapter 6: Research and Development
Malaria
Clinical Trials in Malaria
Leishmaniasis
Clinical Trials in Leishmaniasis
Schistosomiasis
Clinical Trials in Schistosomiasis
Lymphatic Filariasis
Clinical Trials in Lymphatic Filariasis
Chagas Disease
Clinical Trials in Chagas Disease
African Trypanosomiasis
Clinical Trials in African Trypanosomiasis
Dengue
Clinical Trials in Dengue
Ebola
Clinical Trials in Ebola
Zika
Clinical Trials in Zika
Chapter 7: Patent Review
Malaria
Patent Review by Assignee
Patent Review by Year
Patent Review by Country
Patent Review by Type
Leishmaniasis
Patent Review by Assignee
Patent Review by Year
Patent Review by Country
Patent Review by Type
Schistosomiasis
Patent Review by Assignee
Patent Review by Year
Patent Review by Country
Patent Review by Type
Lymphatic Filariasis
Patent Review by Assignee
Patent Review by Year
Patent Review by Country
Patent Review by Type
Chagas Disease
Patent Review by Assignee
Patent Review by Year
Patent Review by Country
Patent Review by Type
African Trypanosomiasis
Patent Review by Assignee
Patent Review by Year
Patent Review by Country
Patent Review by Type
Dengue
Patent Review by Assignee
Patent Review by Year
Patent Review by Country
Patent Review by Type
Ebola
Patent Review by Assignee
Patent Review by Year
Patent Review by Country
Patent Review by Type
Zika
Patent Review by Assignee
Patent Review by Year
Patent Review by Country
Patent Review by Type
Chapter 8: Company Profiles
Appendix: Abbreviations
About BCC Research
About BCC Research
BCC Library Access
BCC Custom Research
List of Tables
Summary Table: Global Market for Neglected Tropical Diseases, by Indication, Through 2021 ($ Millions)
Table 1 Key Trends in Neglected Tropical Diseases
Table 2 Estimated Malaria Incidence (per 1,000 at Risk), 2000-2015
Table 3 Suspected Malaria Cases, 2010-2015 (Millions)
Table 4 Confirmed Malaria Cases, 2010-2015 (Millions)
Table 5 Estimated Spending on Malaria Treatment in Sub-Saharan Africa, 2010-2014 ($ Millions)
Table 6 WHO Guidelines for Treatment of Malaria
Table 7 Number of Cases of CL in Select High Burden Countries, 2010-2014
Table 8 Number of Cases of VL in Select High Burden Countries, 2010-2014
Table 9 Incidence of CL and VL in High Burden Countries, 2014 (Cases per 10,000 Inhabitants in Endemic Areas)
Table 10 Global Disease Burden of Leishmaniasis, 2015
Table 11 WHO Guidelines for Treatment of Leishmaniasis
Table 12 Number of People Treated Globally, 2010-2014 (Millions)
Table 13 Global Disease Burden of Schistosomiasis, 2015 (Years)
Table 14 Global Disease Burden of Lymphatic Filariasis, 2015 (Years)
Table 15 Prevalence and Incidence (Number) of Chagas Disease, 2015
Table 16 Global Disease Burden of Chagas Disease, 2015 (Years)
Table 17 Prevalence and Incidence (Number) of Chagas Disease, 2015
Table 18 Global Disease Burden of African Trypanosomiasis, 2015
Table 19 Prevalence and Incidence (Number) of Dengue Cases, 2015
Table 20 Reported Cases and Deaths in Ebola Outbreaks, 2007-2016
Table 21 Zika Burden, 2015-2016
Table 22 Global Addressable Market for Neglected Tropical Diseases, by Indication, Through 2021 ($ Millions)
Table 23 Global Addressable Market for Malaria, by Region, Through 2021 ($ Millions)
Table 24 Global Addressable Market for Leishmaniasis, by Region, Through 2021 ($ Millions)
Table 25 Global Addressable Market for Schistosomiasis, by Region, Through 2021 ($ Millions)
Table 26 Global Addressable Market for Lymphatic Filariasis, by Region, Through 2021 ($ Millions)
Table 27 Global Addressable Market for Chagas Disease, by Geography, Through 2021 ($ Millions)
Table 28 Global Addressable Market for Dengue, by Region, Through 2021 ($ Millions)
Table 29 Global Addressable Market for Zika, by Region, Through 2021 ($ Millions)
Table 30 Drug Donation Commitments, by WHO
Table 31 Malaria Development Pipeline and Recent Launches
Table 32 Leishmaniasis Development Pipeline and Recent Launches
Table 33 Schistosomiasis Development Pipeline and Recent Launches
Table 34 Lymphatic Filariasis Development Pipeline and Recent Launches
Table 35 Chagas Disease Development Pipeline and Recent Launches
Table 36 African Trypanosomiasis Development Pipeline and Recent Launches
Table 37 Dengue Development Pipeline and Recent Launches
Table 38 Ebola Development Pipeline and Recent Launches
Table 39 Zika Development Pipeline and Recent Launches
Table 40 Number of Patent Applications, Malaria, by Assignee
Table 41 Number of Patent Applications, Malaria, by Year, 2010-2015
Table 42 Number of Patent Applications, Malaria, by Country
Table 43 Number of Patent Applications, Malaria, by Type
Table 44 Number of Patent Applications, Leishmaniasis, by Assignee
Table 45 Number of Patent Applications, Leishmaniasis, by Year, 2010-2015
Table 46 Number of Patent Applications, Leishmaniasis, by Country
Table 47 Number of Patent Applications, Leishmaniasis, by Type
Table 48 Number of Patent Applications, Schistosomiasis, by Assignee
Table 49 Number of Patent Applications, Schistosomiasis, by Year, 2010-2015
Table 50 Number of Patent Applications, Schistosomiasis, by Country
Table 51 Number of Patent Applications, Schistosomiasis, by Type
Table 52 Number of Patent Applications, Lymphatic Filariasis, by Assignee
Table 53 Number of Patent Applications, Lymphatic Filariasis, by Year, 2010-2015
Table 54 Number of Patent Applications, Lymphatic Filariasis, by Country
Table 55 Number of Patent Applications, Lymphatic Filariasis, by Type
Table 56 Number of Patent Applications, Chagas Disease, by Assignee
Table 57 Number of Patent Applications, Chagas Disease, by Year, 2010-2015
Table 58 Number of Patent Applications, Chagas Disease, by Country
Table 59 Number of Patent Applications, Chagas Disease, by Type
Table 60 Number of Patent Applications, African Trypanosomiasis, by Assignee
Table 61 Number of Patent Applications, African Trypanosomiasis, by Year, 2010-2015
Table 62 Number of Patent Applications, African Trypanosomiasis, by Country
Table 63 Number of Patent Applications, African Trypanosomiasis, by Type
Table 64 Number of Patent Applications, Dengue, by Assignee
Table 65 Number of Patent Applications, Dengue, by Year, 2010-2015
Table 66 Number of Patent Applications, Dengue, by Country
Table 67 Number of Patent Applications, Dengue, by Type
Table 68 Number of Patent Applications, Ebola, by Assignee
Table 69 Number of Patent Applications, Ebola, by Year, 2010-2016
Table 70 Number of Patent Applications, Ebola, by Country
Table 71 Number of Patent Applications, Ebola, by Type
Table 72 Number of Patent Applications, Zika, by Assignee
Table 73 Number of Patent Applications, Zika, by Year, 2010-2016
Table 74 Number of Patent Applications, Zika, by Country
Table 75 Number of Patent Applications, Zika, by Type
Table 76 Abbreviations Used in Neglected Tropical Diseases Landscape
Table 77 Glossary of Terms Used in Neglected Tropical Diseases Landscape
Table 78 Report Sources
List of Figures
Summary Figure: Global Market for Neglected Tropical Diseases, by Indication, 2015-2021 ($ Millions)
Figure 1 Global Number of Malaria Caused Deaths, 2011-2015
Figure 2 Global Number of Leishmaniasis Caused Deaths, 2011-2015
Figure 3 Global Leishmaniasis Years of Life Lost*, 2011-2015
Figure 4 Global Number of Schistosomiasis Caused Deaths, 2011-2015
Figure 5 Global Schistosomiasis Years of Life Lost*, 2011-2015
Figure 6 Number of Lymphatic Filariasis Endemic Countries, by Region
Figure 7 Number of Chagas Disease Caused Deaths, 2011-2015
Figure 8 Global Chagas Disease Years of Life Lost*, 2011-2015
Figure 9 Number of Cases of African Trypanosomiasis, T.b. gambiense, 2011-2015
Figure 10 Number of Cases of African Trypanosomiasis, T.b. rhodesiense, 2011-2015
Figure 11 Global Number of African Trypanosomiasis Caused Deaths, 2011-2015
Figure 12 Global African Trypanosomiasis Years of Life Lost*, 2011-2015
Figure 13 Average Annual Number of Dengue Fever Cases, 1960-2007
Figure 14 Number of Cases in American Region, 2012-2016
Figure 15 Incidence Rate (per 100,000 Inhabitants) in American Region, 2012-2016
Figure 16 Global Number of Dengue Caused Deaths, 2011-2015
Figure 17 Global Dengue Caused Years of Life Lost*, 2011-2015
Figure 18 Outbreaks in West Africa Affected Countries (Guinea, Liberia, Sierra Leone), by Total Number of Cases, March 2014-February 2016
Figure 19 Outbreaks in West Africa Affected Countries (Guinea, Liberia, Sierra Leone), by Total Number of Deaths, March 2014-February 2016
Figure 20 Number of Countries (Y) with Number of Confirmed Zika Cases (X), by American Region, 2015-2016
Figure 21 Global Addressable Market for Neglected Tropical Diseases, by Indication, 2015-2021 ($ Millions)
Figure 22 Global Market for Malaria, by Region, 2014-2021 ($ Millions)
Figure 23 Global Market for Leishmaniasis, by Region, 2014-2021 ($ Millions)
Figure 24 Global Market for Schistosomiasis, by Region, 2014-2021 ($ Millions)
Figure 25 Global Market for Lymphatic Filariasis, by Region, 2014-2021 ($ Millions)
Figure 26 Global Market for Chagas Disease, by Geography, 2014-2021 ($ Millions)
Figure 27 Global Market for Dengue, by Region, 2014-2021 ($ Millions)
Figure 28 Global Market for Zika, by Region, 2014-2021 ($ Millions)
Figure 29 Clinical Trials in Malaria, by Intervention Type, January 2005-September 2016 (%)
Figure 30 Top 20 Sponsors/Collaborators, by Clinical Trials in Malaria, January 2005-September 2016 91
Figure 31 Clinical Trials in Leishmaniasis, by Intervention Type, January 2005-September 2016 (%)
Figure 32 Key Sponsors/Collaborators, Clinical Trials in Leishmaniasis, January 2005-September 2016 94
Figure 33 Clinical Trials in Schistosomiasis, by Intervention Type, January 2005-September 2016 (%)
Figure 34 Key Sponsors/Collaborators, Clinical Trials in Lymphatic Filariasis, January 2005-September 2016
Figure 35 Clinical Trials in Chagas Disease, by Intervention Type, January 2005-September 2016 (%)
Figure 36 Key Sponsors/Collaborators, Clinical Trials in Chagas Disease, January 2005-September 2016
Figure 37 Clinical Trials in Dengue, by Intervention Type, January 2005-September 2016 (%)
Figure 38 Key Sponsors/Collaborators, Clinical Trials in Dengue, January 2005-September 2016
Figure 39 Clinical Trials in Ebola, by Intervention Type, January 2005-September 2016 (%)
Figure 40 Key Sponsors/Collaborators, Clinical Trials in Ebola, January 2005-September 2016
Figure 41 Key Sponsors/Collaborators, Clinical Trials in Zika, January 2005-September 2016
Figure 42 Patent Share for Treatment and Preventive Medicine in Malaria, by Year (%)
Figure 43 Patent Share for Treatment and Preventive Medicine in Malaria, US and non-US (%)
Figure 44 Patent Share for Treatment and Preventive Medicine in Leishmaniasis, by Year (%)
Figure 45 Patent Share for Leishmaniasis, US and non-US (%)
Figure 46 Patent Share for Treatment and Preventive Medicine in Schistosomiasis, by Year (%)
Figure 47 Patent Share for Schistosomiasis, U.S. and non-U.S. (%)
Figure 48 Patent Share for Treatment and Preventive Medicine in Lymphatic Filariasis, by Year (%)
Figure 49 Patent Share for Lymphatic Filariasis, U.S. and non-U.S. (%)
Figure 50 Patent Share for Treatment and Preventive Medicine in Chagas Disease, by Year (%)
Figure 51 Patent Share for Chagas Disease, by U.S. and non-U.S. (%)
Figure 52 Patent Share for Treatment and Preventive Medicine in African Trypanosomiasis, by Year (%)
Figure 53 Patent Share for African Trypanosomiasis, US and non-US (%)
Figure 54 Patent Share for Treatment and Preventive Medicine in Dengue, by Year (%)
Figure 55 Patent Share for Dengue, U.S. and non-U.S. (%)
Figure 56 Patent Share for Treatment and Preventive Medicine in Ebola, by Year (%)
Figure 57 Patent Share for Ebola, U.S. and non-U.S. (%)
Figure 58 Patent Share for Treatment and Preventive Medicine in Zika, by Year (%)
Figure 59 Patent Share for Zika, U.S. and Non-U.S. (%)
Figure 60 DNDi – Research Portfolio, by Phase of Development (%)
Figure 61 DNDi – Research Portfolio, by Indication (%)
Figure 62 GlaxoSmithKline – Research Portfolio, by Phase of Development (%)
Figure 63 GlaxoSmithKline – Research Portfolio, by Indication (%)
Figure 64 MMV – Research Portfolio, by Phase of Development
Figure 65 MMV – Research Portfolio, by Partner (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report